
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9097595/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Clinicopathologic analysis of patients undergoing repeat transurethral resection of bladder tumour following an initial diagnosis of urothelial carcinoma with lamina propria invasion and variant/divergent histology. Journal of Clinical Pathology, 2023, 76, 256-260.	1.0	0
2	Correlates of financial toxicity in adult cancer patients and their informal caregivers. Supportive Care in Cancer, 2022, 30, 217-225.	1.0	34
3	Association of prior local therapy and outcomes with programmedâ€death ligandâ€1 inhibitors in advanced urothelial cancer. BJU International, 2022, 130, 592-603.	1.3	3
4	Analysis of Toxicity and Clinical Outcomes in Full Versus Reduced Starting Dose Cabozantinib in Metastatic Renal Cell Carcinoma Patients. Clinical Genitourinary Cancer, 2022, 20, 53-59.	0.9	4
5	Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial. Clinical Cancer Research, 2022, 28, 738-747.	3.2	11
6	Risk Stratification of Prostatic Adenocarcinoma Metastatic to the Lymph Nodes. Archives of Pathology and Laboratory Medicine, 2022, 146, 1345-1352.	1.2	1
7	The prognostic role of sarcopenia and albumin in locally advanced renal cell carcinoma with IVC tumor thrombus Journal of Clinical Oncology, 2022, 40, 387-387.	0.8	1
8	Initial results of a phase II study of nivolumab(N) and ipilimumab(I) in genitourinary malignancies with neuroendocrine differentiation Journal of Clinical Oncology, 2022, 40, 569-569.	0.8	0
9	Sarcopenia as a predictor of perioperative morbidity in metastatic renal cell carcinoma patients undergoing radical nephrectomy and IVC tumor thrombectomy Journal of Clinical Oncology, 2022, 40, 388-388.	0.8	0
10	Immuno-oncology (IO) combinations +/- VEGF targeted therapy (VEGF TT) in patients (pts) with advanced mit family translocation renal cell carcinomas (tRCC): Results from an international multicenter study Journal of Clinical Oncology, 2022, 40, 343-343.	0.8	1
11	Implications of androgen receptor (AR) alterations identified by genomic testing of tissue and blood from advanced prostate cancer (aPC) patients (pts) Journal of Clinical Oncology, 2022, 40, 138-138.	0.8	0
12	DNA damaging therapies in patients (pts) with prostate cancer (PC) and pathogenic alterations in homologous recombination repair (HRR) genes Journal of Clinical Oncology, 2022, 40, 129-129.	0.8	0
13	Molecular alterations across sites of metastasis in patients with renal cell carcinoma (RCC) Journal of Clinical Oncology, 2022, 40, 287-287.	0.8	2
14	Phase 2 study of neoadjuvant cabozantinib in patients with locally advanced non-metastatic clear cell renal cell carcinoma Journal of Clinical Oncology, 2022, 40, 340-340.	0.8	4
15	Comprehensive genomic profiling of penile squamous cell carcinoma and impact of HPV status on immune-checkpoint inhibition-related biomarkers Journal of Clinical Oncology, 2022, 40, 4-4.	0.8	2
16	Blood-based tumor mutational burden from circulating tumor DNA and immune checkpoint inhibitors in advanced prostate cancer Journal of Clinical Oncology, 2022, 40, 165-165.	0.8	1
17	Mixed methods assessment of providers' needs in the management of advanced renal cell carcinoma Journal of Clinical Oncology, 2022, 40, 313-313.	0.8	0
18	Clinical outcomes in advanced urothelial cancer (UC) patients who experienced immune-related adverse events (irAEs) after immune checkpoint inhibitor monotherapy (ICI) Journal of Clinical Oncology, 2022, 40, 544-544.	0.8	0

#	Article	IF	CITATIONS
19	Expression of Nectin-4 and PD-L1 in bladder cancer with variant histology Journal of Clinical Oncology, 2022, 40, 529-529.	0.8	4
20	Study EV-103 cohort L: Evaluating perioperative enfortumab vedotin monotherapy in cis-ineligible muscle invasive bladder cancer (MIBC) (trial in progress) Journal of Clinical Oncology, 2022, 40, TPS587-TPS587.	0.8	5
21	Racial Disparities in COVID-19 Outcomes Among Black and White Patients With Cancer. JAMA Network Open, 2022, 5, e224304.	2.8	43
22	Advances in Knowledge and Management of Immune-Related Adverse Events in Cancer Immunotherapy. Frontiers in Endocrinology, 2022, 13, 779915.	1.5	15
23	Sarcopenia and systemic inflammation are associated with decreased survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. Cancer, 2022, 128, 2073-2084.	2.0	6
24	Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study. , 2022, 10, e004419.		8
25	Baseline basophil and basophil-to-lymphocyte status is associated with clinical outcomes in metastatic hormone sensitive prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 271.e9-271.e18.	0.8	6
26	Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma. Clinical Genitourinary Cancer, 2022, 20, e440-e452.	0.9	10
27	Raising the level of cancer care: Feasibility and reported benefit of a virtual tumor board Journal of Clinical Oncology, 2022, 40, e18595-e18595.	0.8	0
28	Combination Immune Checkpoint Blockade Regimens for Previously Untreated Metastatic Renal Cell Carcinoma: The Winship Cancer Institute of Emory University Experience. Journal of Immunotherapy and Precision Oncology, 2022, , .	0.6	1
29	An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma. Ca-A Cancer Journal for Clinicians, 2022, 72, 454-489.	157.7	13
30	Comparison of sociodemographic characteristics of a phase 1 clinical trial population at an NCI-designated comprehensive cancer center in the Southeast to catchment area Journal of Clinical Oncology, 2022, 40, e18591-e18591.	0.8	0
31	A randomized phase Ib/II study of intermittent androgen deprivation therapy plus nivolumab with or without interleukin-8 blockade in men with hormone-sensitive prostate cancer (MAGIC-8) Journal of Clinical Oncology, 2022, 40, 5082-5082.	0.8	3
32	Outcomes with novel combinations in nonclear cell renal cell carcinoma (nccRCC): ORACLE study Journal of Clinical Oncology, 2022, 40, 4545-4545.	0.8	1
33	Biomarker-directed therapy in black and white men with metastatic castration-resistant prostate cancer (mCRPC) Journal of Clinical Oncology, 2022, 40, 5013-5013.	0.8	0
34	Phase la dose-escalation study of the anti-BTLA antibody icatolimab as a monotherapy in patients with advanced solid tumor Journal of Clinical Oncology, 2022, 40, 2643-2643.	0.8	9
35	PIVOT-10: Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancer. Future Oncology, 2021, 17, 137-149.	1.1	5
36	Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies. Cancer, 2021, 127, 840-849.	2.0	51

#	Article	IF	CITATIONS
37	Bladder preserving chemoradiotherapy compared to surgery for variants of urothelial carcinoma and other tumors types involving the bladder: An analysis of the National Cancer Database. Clinical and Translational Radiation Oncology, 2021, 26, 30-34.	0.9	8
38	Novel risk scoring system for metastatic renal cell carcinoma patients treated with cabozantinib. Cancer Treatment and Research Communications, 2021, 28, 100393.	0.7	2
39	Phase II trial of opaganib in patients with metastatic castration-resistant prostate cancer progressing on abiraterone or enzalutamide (NCT04207255) Journal of Clinical Oncology, 2021, 39, TPS191-TPS191.	0.8	1
40	Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes. BJU International, 2021, 128, 196-205.	1.3	18
41	Association between sites of metastases (mets) and outcomes with immune checkpoint inhibitor (ICI) therapy for advanced urothelial carcinoma (aUC) Journal of Clinical Oncology, 2021, 39, 445-445.	0.8	2
42	Real-world prevalence of homologous recombination repair gene (BRCA1/2 and ATM) mutations (HRRm) in patients (pts) with advanced prostate cancer (aPC) as detected by comprehensive genomic profiling (CGP) of circulating cell-free DNA (cfDNA) Journal of Clinical Oncology, 2021, 39, 256-256.	0.8	0
43	Differences in the genomic landscape of advanced prostate cancer (aPC) patients (pts) with BRCA1 versus BRCA2 mutations as detected by machine learning analysis of the comprehensive genomic profile (CGP) of cell-free DNA (cfDNA) Journal of Clinical Oncology, 2021, 39, 162-162.	0.8	0
44	Association between prior radical surgery (RS) and outcomes with immune checkpoint inhibitor (ICI) therapy for advanced urothelial carcinoma (aUC) Journal of Clinical Oncology, 2021, 39, 444-444.	0.8	0
45	Multi-institutional evaluation of the clinical outcomes and genomic correlates of African Americans with metastatic castration-sensitive prostate cancer (mCSPC) Journal of Clinical Oncology, 2021, 39, 17-17.	0.8	0
46	Landscape of circulating tumor DNA (ctDNA) abnormalities in advanced prostate cancer (aPCa): Distinctions in African American (AA) versus Caucasian (Ca) patients Journal of Clinical Oncology, 2021, 39, 156-156.	0.8	0
47	Symptomatic methemoglobinemia in a patient with metastatic clear cell renal cell carcinoma treated with pembrolizumab and axitinib combination therapy: a case report. Journal of Medical Case Reports, 2021, 15, 72.	0.4	1
48	Efficacy of cabozantinib in advanced MiT family translocation renal cell carcinomas (TRCC) Journal of Clinical Oncology, 2021, 39, 274-274.	0.8	8
49	Sarcopenia and modified Glasgow Prognostic Score predict postsurgical outcomes in localized renal cell carcinoma. Cancer, 2021, 127, 1974-1983.	2.0	26
50	Baseline Modified Glasgow Prognostic Score Associated with Survival in Metastatic Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors. Oncologist, 2021, 26, 397-405.	1.9	14
51	Segmentation and Linear Measurement for Body Composition Analysis using Slice-O-Matic and Horos. Journal of Visualized Experiments, 2021, , .	0.2	11
52	Detection of Microsatellite Instability via Circulating Tumor DNA and Response to Immunotherapy in Metastatic Castration-Resistant Prostate Cancer: A Case Series. Case Reports in Oncology, 2021, 14, 190-196.	0.3	10
53	Inflammatory Markers in Cancer Immunotherapy. Biology, 2021, 10, 325.	1.3	28
54	Baseline neutrophil-to-eosinophil ratio (NER) and its association with clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (CPI) Journal of Clinical Oncology, 2021, 39, e16569-e16569.	0.8	0

#	Article	IF	CITATIONS
55	Outcomes of patients (pts) with advanced urothelial carcinoma (aUC) treated with immune checkpoint inhibitors (ICIs): Associations with age, race, sex and smoking history Journal of Clinical Oncology, 2021, 39, e16526-e16526.	0.8	0
56	18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial. Lancet, The, 2021, 397, 1895-1904.	6.3	107
57	Baseline modified Clasgow prognostic score (mGPS) in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI) Journal of Clinical Oncology, 2021, 39, e16546-e16546.	0.8	0
58	Differences in the tumor genomic landscape between African Americans (AA) and Caucasians (CA) advanced prostate cancer (aPC) patients (pts) by comprehensive genomic profiling (CGP) of cell-free DNA (cfDNA) Journal of Clinical Oncology, 2021, 39, 5058-5058.	0.8	1
59	Misunderstanding immunotherapy: An analysis of provider-patient conversations Journal of Clinical Oncology, 2021, 39, e18638-e18638.	0.8	0
60	Clinical outcomes in metastatic renal cell carcinoma (mRCC) treated with combination of nivolumab and cabozantinib (nivo-cabo) in the salvage setting Journal of Clinical Oncology, 2021, 39, e16570-e16570.	0.8	1
61	Association of basophil to lymphocyte ratio (BLR) with clinical outcomes in metastatic hormone sensitive prostate cancer Journal of Clinical Oncology, 2021, 39, e17049-e17049.	0.8	0
62	Circulating tumor DNA (ctDNA) in patients with advanced adrenocortical carcinoma Journal of Clinical Oncology, 2021, 39, 4585-4585.	0.8	1
63	Blood-based tumor mutational burden from circulating tumor DNA (ctDNA) across advanced solid malignancies using a commercially available liquid biopsy assay Journal of Clinical Oncology, 2021, 39, 3040-3040.	0.8	9
64	Racial and ethnic disparities among patients with breast cancer and COVID-19 Journal of Clinical Oncology, 2021, 39, 6500-6500.	0.8	0
65	Racial Differences in Clinical Outcomes for Metastatic Renal Cell Carcinoma Patients Treated With Immune-Checkpoint Blockade. Frontiers in Oncology, 2021, 11, 701345.	1.3	4
66	Clinical Outcomes and Racial Disparities in Metastatic Hormone-Sensitive Prostate Cancer in the Era of Novel Treatment Options. Oncologist, 2021, 26, 956-964.	1.9	7
67	A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors. European Urology Oncology, 2021, 4, 464-472.	2.6	39
68	Body Composition Variables as Radiographic Biomarkers of Clinical Outcomes in Metastatic Renal Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors. Frontiers in Oncology, 2021, 11, 707050.	1.3	19
69	Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study. Lancet Oncology, The, 2021, 22, 946-958.	5.1	100
70	Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. Oncologist, 2021, 26, e1742-e1750.	1.9	17
71	Retrospective Study of Bleeding Risk with Concomitant Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor and Anticoagulation. Oncologist, 2021, 26, e2061-e2069.	1.9	8
72	Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors. , 2021, 9, e002851.		12

#	Article	IF	CITATIONS
73	Small-Cell Carcinoma of the Prostate: Report of Outcomes of Localized Disease Using the National Cancer Database. Clinical Genitourinary Cancer, 2021, 19, e193-e199.	0.9	1
74	Body Composition as an Independent Predictive and Prognostic Biomarker in Advanced Urothelial Carcinoma Patients Treated with Immune Checkpoint Inhibitors. Oncologist, 2021, 26, 1017-1025.	1.9	18
75	Clinical Outcomes of Platinum-ineligible Patients with Advanced Urothelial Carcinoma Treated With First-line PD1/L1 Inhibitors. Clinical Genitourinary Cancer, 2021, 19, 425-433.	0.9	15
76	Successful Recruitment of Black Men to Prostate Cancer Clinical Trials—A Lesson in Achievement. JAMA Network Open, 2021, 4, e2034652.	2.8	1
77	Impact of Sarcopenia, BMI, and Inflammatory Biomarkers on Survival in Advanced Hepatocellular Carcinoma Treated With Anti-PD-1 Antibody. American Journal of Clinical Oncology: Cancer Clinical Trials, 2021, 44, 74-81.	0.6	36
78	Immunotherapies in Genitourinary Oncology: Where Are We Now? Where Are We Going?. Cancers, 2021, 13, 5065.	1.7	13
79	Circulating interleukin 6, androgen deprivation therapy, and fatigue in prostate cancer: Is inflammation the link?. Cancer, 2021, 127, 1371-1373.	2.0	2
80	Poorly Differentiated Neuroendocrine Tumor With 18F-Fluciclovine Uptake in a Patient With Metastatic Castrate-Resistant Prostate Cancer. Clinical Nuclear Medicine, 2021, 46, e282-e285.	0.7	4
81	Exploratory study of F-fluciclovine pet/ct for response assessment to docetaxel in patients with metastatic castration-resistant prostate cancer. American Journal of Nuclear Medicine and Molecular Imaging, 2021, 11, 218-229.	1.0	1
82	Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19. JAMA Network Open, 2021, 4, e2134330.	2.8	32
83	Landscape of Immunotherapy in Genitourinary Malignancies. Advances in Experimental Medicine and Biology, 2021, 1342, 143-192.	0.8	2
84	Case Report: Exceptional Response to Nivolumab Plus Ipilimumab in a Young Woman With TFE3-SFPQ Fusion Translocation-Associated Renal Cell Carcinoma. Frontiers in Oncology, 2021, 11, 793808.	1.3	2
85	Adiposity may predict survival in patients with advanced stage cancer treated with immunotherapy in phase 1 clinical trials. Cancer, 2020, 126, 575-582.	2.0	65
86	Multidisciplinary Care of Adult Wilms' Tumor During Pregnancy: A Case Report and Review of the Literature. Clinical Genitourinary Cancer, 2020, 18, e1-e4.	0.9	6
87	Combined Effect of Sarcopenia and Systemic Inflammation on Survival in Patients with Advanced Stage Cancer Treated with Immunotherapy. Oncologist, 2020, 25, e528-e535.	1.9	44
88	Novel Risk Scoring System for Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. Oncologist, 2020, 25, e484-e491.	1.9	29
89	Impact of performance status on treatment outcomes: A realâ€world study of advanced urothelial cancer treated with immune checkpoint inhibitors. Cancer, 2020, 126, 1208-1216.	2.0	70
90	Quantification of body composition in renal cell carcinoma patients: Comparing computed tomography and magnetic resonance imaging measurements. European Journal of Radiology, 2020, 132, 109307.	1.2	11

#	Article	IF	CITATIONS
91	Outcomes With First-Line PD-1/PD-L1 Inhibitor Monotherapy for Metastatic Renal Cell Carcinoma (mRCC): A Multi-Institutional Cohort. Frontiers in Oncology, 2020, 10, 581189.	1.3	11
92	Phase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinoma. British Journal of Cancer, 2020, 123, 1228-1234.	2.9	6
93	A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance. Cancer Cell, 2020, 38, 761-766.	7.7	26
94	Immunotherapy in sarcomatoid renal cell carcinoma: A case for optimism. Cancer Treatment and Research Communications, 2020, 25, 100257.	0.7	0
95	Skeletal-Related Events in Patients with Metastatic Renal Cell Carcinoma: A Systematic Review. Kidney Cancer, 2020, 4, 93-102.	0.2	1
96	Dynamic Evaluation of the Modified Glasgow Prognostic Scale in Patients With Resected, Localized Clear Cell Renal Cell Carcinoma. Urology, 2020, 141, 101-107.	0.5	4
97	Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet, The, 2020, 395, 1907-1918.	6.3	1,395
98	A Phase I Study of Safety, Pharmacokinetics, and Pharmacodynamics of Concurrent Everolimus and Buparlisib Treatment in Advanced Solid Tumors. Clinical Cancer Research, 2020, 26, 2497-2505.	3.2	9
99	In Reply. Oncologist, 2020, 25, e876.	1.9	0
100	Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy. Oncologist, 2020, 25, 669-679.	1.9	30
101	Novel risk group stratification for metastatic urothelial cancer patients treated with immune checkpoint inhibitors. Cancer Medicine, 2020, 9, 2752-2760.	1.3	13
102	Reply to Body fat indices and survival in immunotherapyâ€ŧreated patients with cancer. Cancer, 2020, 126, 3157-3159.	2.0	0
103	Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma. , 2020, 8, e000144.		56
104	Nonbacterial Thrombotic Endocarditis and Widespread Skin Necrosis in Newly Diagnosed Lung Adenocarcinoma. Case Reports in Oncology, 2020, 13, 239-244.	0.3	4
105	Neoadjuvant Cabozantinib in an Unresectable Locally Advanced Renal Cell Carcinoma Patient Leads to Downsizing of Tumor Enabling Surgical Resection: A Case Report. Frontiers in Oncology, 2020, 10, 622134.	1.3	4
106	Current Landscape of Immunotherapy in Genitourinary Malignancies. Advances in Experimental Medicine and Biology, 2020, 1244, 107-147.	0.8	3
107	Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naÃ ⁻ ve patients (pts) with advanced renal cell carcinoma (RCC) (HCRN GU16-260) Journal of Clinical Oncology, 2020, 38, 5006-5006.	0.8	48
108	Phase II study of nivolumab and ipilimumab for advanced rare genitourinary cancers Journal of Clinical Oncology, 2020, 38, 5018-5018.	0.8	9

#	Article	IF	CITATIONS
109	Study EV-103: Durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma Journal of Clinical Oncology, 2020, 38, 5044-5044.	0.8	13
110	First-line PD-1/PD-L1 inhibitor monotherapy for advanced renal cell carcinoma (aRCC): A multi-institutional cohort Journal of Clinical Oncology, 2020, 38, e17109-e17109.	0.8	2
111	Study EV-103: New randomized cohort testing enfortumab vedotin as monotherapy or in combination with pembrolizumab in locally advanced or metastatic urothelial cancer Journal of Clinical Oncology, 2020, 38, TPS5092-TPS5092.	0.8	4
112	Clinical impact of COVID-19 on patients with cancer: Data from the COVID-19 and Cancer Consortium (CCC19) Journal of Clinical Oncology, 2020, 38, LBA110-LBA110.	0.8	15
113	Study EV-103: Preliminary durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma Journal of Clinical Oncology, 2020, 38, 441-441.	0.8	79
114	Association of baseline modified Glasgow Prognostic Score (mGPS) with survival outcomes in patients with metastatic urothelial cell carcinoma (mUCC) treated with immune checkpoint inhibitors (CPI) Journal of Clinical Oncology, 2020, 38, 563-563.	0.8	1
115	Association of modified Glasgow Prognostic Score (mGPS) with survival outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (CPI) Journal of Clinical Oncology, 2020, 38, 738-738.	0.8	1
116	Real-world prognostic model for overall survival (OS) in patients (pts) with advanced urothelial cancer (aUC) treated with immune checkpoint inhibitors (ICI) Journal of Clinical Oncology, 2020, 38, 447-447.	0.8	0
117	The impact of inflammatory biomarkers, BMI, and sarcopenia on survival in advanced hepatocellular carcinoma treated with immunotherapy Journal of Clinical Oncology, 2020, 38, 553-553.	0.8	1
118	The real-world efficacy of abiraterone acetate (ABA) and docetaxel (DOC) in the treatment of African-American (AA) patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) Journal of Clinical Oncology, 2020, 38, 52-52.	0.8	0
119	Novel risk scoring system for metastatic renal cell carcinoma (mRCC) patients (pts) treated with cabozantinib (C) Journal of Clinical Oncology, 2020, 38, 734-734.	0.8	7
120	PIVOT-10: A phase II study of bempegaldesleukin (NKTR-214) in combination with nivolumab (NIVO) in cisplatin (cis) ineligible patients with previously untreated locally advanced or metastatic urothelial cancer (mUC) Journal of Clinical Oncology, 2020, 38, TPS589-TPS589.	0.8	0
121	Circulating tumor (ct) DNA-based comprehensive genomic profiling to identify microsatellite instability (MSI) and defective DNA damage repair (DDR) in prostate cancer (PCa) patients Journal of Clinical Oncology, 2020, 38, 190-190.	0.8	Ο
122	Olaparib (O) in patients (pts) with prostate cancer with BRCA1/2 inactivating mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study Journal of Clinical Oncology, 2020, 38, 5567-5567.	0.8	2
123	Histologic subtype and response to immune checkpoint inhibitor (ICI) therapy in advanced urothelial cancer (aUC) Journal of Clinical Oncology, 2020, 38, 495-495.	0.8	0
124	Outcomes of adult urogenital sarcomas: Analysis of surveillance, epidemiology, and end results (SEER) database 2004 to 2015 Journal of Clinical Oncology, 2020, 38, 423-423.	0.8	0
125	The role of 68Ga-DOTATATE for evaluation of patients with metastatic castration-resistant prostate cancer (mCRPC) Journal of Clinical Oncology, 2020, 38, 217-217.	0.8	3
126	A risk scoring system for African-American (AA) patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line abiraterone (ABA) or enzalutamide (ENZ) Journal of Clinical Oncology, 2020, 38, 51-51.	0.8	0

#	Article	IF	CITATIONS
127	Considerations for cancer immunotherapy biomarker research during COVID-19. Endocrine-Related Cancer, 2020, 27, C1-C8.	1.6	0
128	Considerations for cancer immunotherapy biomarker research during COVID-19. Endocrine-Related Cancer, 2020, 27, C1-C8.	1.6	0
129	Comparison of Outcomes in Patients With Muscle-invasive Bladder Cancer Treated With Radical Cystectomy Versus Bladder Preservation. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 36-41.	0.6	41
130	A Review of Papillary Renal Cell Carcinoma and MET Inhibitors. Kidney Cancer, 2019, 3, 151-161.	0.2	45
131	Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy. BMC Cancer, 2019, 19, 857.	1.1	88
132	Management of metastatic renal cell carcinoma: The complexity of choice. EBioMedicine, 2019, 47, 2-3.	2.7	1
133	Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trials. Investigational New Drugs, 2019, 37, 1198-1206.	1.2	11
134	Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study. Lancet Oncology, The, 2019, 20, 581-590.	5.1	124
135	Reply to Tumorâ€associated macrophages: "Good copâ€bad cop― Cancer, 2019, 125, 1942-1943.	2.0	0
136	An intra-tumoral niche maintains and differentiates stem-like CD8 T cells. Nature, 2019, 576, 465-470.	13.7	510
137	Hybrid negative enrichment of circulating tumor cells from whole blood in a 3D-printed monolithic device. Lab on A Chip, 2019, 19, 3427-3437.	3.1	33
138	Circulating tumor DNA alterations in patients with metastatic castrationâ€resistant prostate cancer. Cancer, 2019, 125, 1459-1469.	2.0	38
139	MRI quantitation of abdominal skeletal muscle correlates with CT-based analysis: implications for sarcopenia measurement. Applied Physiology, Nutrition and Metabolism, 2019, 44, 814-819.	0.9	33
140	The prognostic and predictive impact of inflammatory biomarkers in patients who have advancedâ€stage cancer treated with immunotherapy. Cancer, 2019, 125, 127-134.	2.0	120
141	NKTR-214 + nivolumab in first-line advanced/metastatic urothelial carcinoma (mUC): Updated results from PIVOT-02 Journal of Clinical Oncology, 2019, 37, 388-388.	0.8	18
142	Sites of metastases (mets) and their association with clinical outcomes (CO) in urothelial cancer patients (pts) treated with immunotherapy (IO) Journal of Clinical Oncology, 2019, 37, 473-473.	0.8	2
143	Safety and efficacy of restarting immune checkpoint inhibitors (CPI) after immune-related adverse events (irAEs) in metastatic renal cell carcinoma (mRCC) Journal of Clinical Oncology, 2019, 37, 652-652.	0.8	4
144	Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA. Cancer, 2018, 124, 2115-2124.	2.0	79

#	Article	IF	CITATIONS
145	Evaluation of programmed cell death protein 1 (PD-1) expression as a prognostic biomarker in patients with clear cell renal cell carcinoma. OncoImmunology, 2018, 7, e1413519.	2.1	21
146	The prospects for combination therapy with capecitabine in the rapidly evolving treatment landscape of renal cell carcinoma. Expert Opinion on Investigational Drugs, 2018, 27, 163-170.	1.9	5
147	Association Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Outcome of Patients With Metastatic Renal-Cell Carcinoma Treated With Nivolumab. Clinical Genitourinary Cancer, 2018, 16, e563-e575.	0.9	72
148	Radiomics to predict immunotherapy-induced pneumonitis: proof of concept. Investigational New Drugs, 2018, 36, 601-607.	1.2	90
149	Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience. Investigational New Drugs, 2018, 36, 638-646.	1.2	149
150	The addition of chemotherapy in the definitive management of high risk prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 475-487.	0.8	6
151	Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis. European Journal of Cancer, 2018, 104, 188-194.	1.3	58
152	Metastatic Prostate Cancer Manifesting as Cholestatic Jaundice: A Case Report and Review of the Literature. Case Reports in Oncological Medicine, 2018, 2018, 1-4.	0.2	3
153	Therapeutic Vaccines for Genitourinary Malignancies. Vaccines, 2018, 6, 55.	2.1	9
154	Safety of Same-day Pegfilgrastim Administration in Metastatic Castration-resistant Prostate Cancer Treated With Cabazitaxel With or Without Carboplatin. Clinical Genitourinary Cancer, 2017, 15, e429-e435.	0.9	10
155	Frailty and cancer: Implications for oncology surgery, medical oncology, and radiation oncology. Ca-A Cancer Journal for Clinicians, 2017, 67, 362-377.	157.7	364
156	Clinical predictors of survival in patients with castration-resistant prostate cancer receiving sipuleucel-T cellular immunotherapy. Cancer Chemotherapy and Pharmacology, 2017, 80, 583-589.	1.1	6
157	A novel preoperative inflammatory marker prognostic score in patients with localized and metastatic renal cell carcinoma. Asian Journal of Urology, 2017, 4, 230-238.	0.5	13
158	Proteomics Profiling of Exosomes from Primary Mouse Osteoblasts under Proliferation versus Mineralization Conditions and Characterization of Their Uptake into Prostate Cancer Cells. Journal of Proteome Research, 2017, 16, 2709-2728.	1.8	43
159	Intratumoral heterogeneity: Role of differentiation in a potentially lethal phenotype of testicular cancer. Cancer, 2016, 122, 1836-1843.	2.0	39
160	Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody. , 2016, 4, 36.		90
161	Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trials. Cancer Chemotherapy and Pharmacology, 2016, 78, 167-171.	1.1	18
162	Intratumoral heterogeneity and chemoresistance in nonseminomatous germ cell tumor of the testis. Oncotarget, 2016, 7, 86280-86289.	0.8	25

#	Article	IF	CITATIONS
163	Randomized phase 2 study of boneâ€ŧargeted therapy containing strontiumâ€89 in advanced castrateâ€sensitive prostate cancer. Cancer, 2015, 121, 69-76.	2.0	13
164	Phase I trial of valproic acid and lenalidomide in patients with advanced cancer. Cancer Chemotherapy and Pharmacology, 2015, 75, 869-874.	1.1	26
165	Cadherin-11 endocytosis through binding to clathrin promotes cadherin-11-mediated migration in prostate cancer cells. Journal of Cell Science, 2015, 128, 4629-41.	1.2	18
166	Hypertension and Circulating Cytokines and Angiogenic Factors in Patients With Advanced Nonâ€Clear Cell Renal Cell Carcinoma Treated With Sunitinib: Results From a Phase II Trial. Oncologist, 2015, 20, 1140-1148.	1.9	13
167	The scientific method: pillar and pitfall of cancer research. Cancer Medicine, 2014, 3, 1035-1037.	1.3	11
168	Positive FDG-PET/CT Scans of a Residual Seminoma After Chemotherapy and Radiotherapy: Case Report and Review of the Literature. Clinical Genitourinary Cancer, 2014, 12, e147-e150.	0.9	6
169	Evaluation of a novel blood pressure scoring method and its association with clinical response in cancer patients treated with anti-vascular endothelial growth factor therapy. Investigational New Drugs, 2014, 32, 717-722.	1.2	3
170	Variant prostate carcinoma and elevated serum CA-125. Canadian Journal of Urology, 2014, 21, 7442-8.	0.0	4
171	Inhibition of Cell Adhesion by a Cadherin-11 Antibody Thwarts Bone Metastasis. Molecular Cancer Research, 2013, 11, 1401-1411.	1.5	41
172	BMP4 Promotes Prostate Tumor Growth in Bone through Osteogenesis . Cancer Research, 2011, 71, 5194-5203.	0.4	120
173	Cadherin-11 Increases Migration and Invasion of Prostate Cancer Cells and Enhances their Interaction with Osteoblasts. Cancer Research, 2010, 70, 4580-4589.	0.4	113
174	Ductal adenocarcinoma of the prostate. Cancer, 2009, 115, 2872-2880.	2.0	56
175	Modulation of prostate cancer cell gene expression by cell-to-cell contact with bone marrow stromal cells or osteoblasts. Clinical and Experimental Metastasis, 2009, 26, 993-1004.	1.7	21